• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Orbimed Advisors Llc sold $900,000 worth of shares (500,000 units at $1.80) (SEC Form 4)

    9/12/25 5:09:08 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMVP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ORBIMED ADVISORS LLC

    (Last) (First) (Middle)
    601 LEXINGTON AVENUE
    54TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PMV Pharmaceuticals, Inc. [ PMVP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/10/2025 S 500,000 D $1.8 5,975,291 I See Footnotes(1)(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    ORBIMED ADVISORS LLC

    (Last) (First) (Middle)
    601 LEXINGTON AVENUE
    54TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    OrbiMed Capital GP V LLC

    (Last) (First) (Middle)
    601 LEXINGTON AVENUE
    54TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment advisor under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.
    2. This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
    /s/ Carl L. Gordon, Member of OrbiMed Advisors 09/12/2025
    /s/ Carl L. Gordon, Member of the Managing Member of OrbiMed Capital GP V LLC 09/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PMVP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMVP

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Perform → Outperform
    Oppenheimer
    5/13/2024$6.00Buy
    Craig Hallum
    4/12/2024$5.00Buy
    Jefferies
    12/27/2023$7.00Buy
    Ladenburg Thalmann
    3/2/2022$30.00Perform → Outperform
    Oppenheimer
    3/2/2022Perform → Outperform
    Oppenheimer
    9/22/2021$35.00 → $43.00Neutral → Buy
    Goldman Sachs
    8/19/2021Perform
    Oppenheimer
    More analyst ratings

    $PMVP
    SEC Filings

    View All

    SEC Form 144 filed by PMV Pharmaceuticals Inc.

    144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    9/10/25 6:50:45 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

    8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    9/10/25 12:04:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.

    SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    8/14/25 4:02:29 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc sold $900,000 worth of shares (500,000 units at $1.80) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    9/12/25 5:09:08 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel & COO Ticktin Robert sold $24,651 worth of shares (23,151 units at $1.06), decreasing direct ownership by 19% to 98,695 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    7/3/25 7:51:53 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Jalota Deepika sold $35,198 worth of shares (33,065 units at $1.06), decreasing direct ownership by 27% to 89,959 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    7/3/25 7:50:11 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PMV Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

    11/8/24 7:58:24 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on PMV Pharmaceuticals with a new price target

    Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    5/13/24 8:31:58 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on PMV Pharmaceuticals with a new price target

    Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    4/12/24 7:35:19 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

    PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027Company to host investor webinar at 8:00 AM ET today to review Phase 2 interim clinical data PRINCETON

    9/10/25 7:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

    PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis   Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June

    8/7/25 8:42:03 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

    PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Tuesday, May 27, 2025Time: 11:30 AM EDT Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025Time: 3:45 PM E

    5/23/25 4:05:00 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Leadership Updates

    Live Leadership Updates

    View All

    PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

    CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in

    11/4/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

    Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr

    3/1/22 7:15:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharma Announces Changes to its Board of Directors

    CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV's Board. "Peter has been an invaluable member of the Board during a period of substantial growth and key successes, including completion of our IPO as well as entry of our lead candidate, PC14586, into the clinic," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "On behalf o

    1/6/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    11/14/24 12:24:48 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    7/8/24 4:32:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care